VarilrixTM

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

MeaslesMumpsRubellaVaricella

Phase 2

Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).

CompletedNCT00792623

GlaxoSmithKlineVaricella

Start: 2003-09-08End: 2007-09-10Updated: 2018-11-08

Phase 3

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

CompletedNCT00751348

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2008-10-01End: 2010-05-27Updated: 2018-06-08

Related Papers

Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation.

2014-10-0111 citations

Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine: an open-labeled, randomized trial in healthy Korean children.

2013-12-187 citations